Form 4 for TSHA Taysha Gene Therapies, Inc.
Accepted 2023-08-16 00:00:00 ET · period of report 2023-08-16 · accession 0001209191-23-046150 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2023-08-16 | 2023-08-16 | TSHA | Nolan Sean P. | CEO, Dir | P - Purchase | $0.9 | +444.4K | 1.54M | +41% | +$400.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-16 | P | A | 444,444 | $0.9 | 1,535,545 | I See Footnote | — | — | (F1) The securities are held by Nolan Capital, LLC (the "LLC"). The Reporting Person is the President of the LLC and has shared voting and investment power with respect to the shares held by the LLC. |